Results 61 to 70 of about 5,671 (151)

Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience

open access: yesTherapeutic Advances in Urology, 2019
More than a million men worldwide are diagnosed with prostate cancer every year. After androgen deprivation therapy (ADT), chemotherapy has been the only subsequent intervention to improve survival in the metastatic setting but has limitations for ...
Karin Purshouse, Andrew S. Protheroe
doaj   +1 more source

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

open access: yesBMC Cancer, 2019
Background Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular ...
Gustavo Werutsky   +15 more
doaj   +1 more source

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients

open access: yesInternational Journal of Hematology-Oncology and Stem Cell Research, 2018
Background: Abiraterone acetate was approved by FDA and EMA in April and September 2011, respectively for treatment of patients with casteration resistant prostate cancer and those previously treated with docetaxel.
Aloysius James   +3 more
doaj  

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations

open access: yesTherapeutics and Clinical Risk Management, 2018
Pietro Castellan,1 Michele Marchioni,2 Roberto Castellucci,1 Piergustavo De Francesco,2 Romina Iantorno,1 Luigi Schips,1,2 Luca Cindolo1 1Department of Urology, ASL02 Abruzzo, Chieti, Italy; 2Department of Urology, University “G.
Castellan P   +6 more
doaj  

Independent association between prostate-specific antigen nadir and PSA progression-free survival in first-line abiraterone acetate treatment in castration-resistant prostate cancer patients: a pilot study

open access: yesFrontiers in Oncology
BackgroundThere is limited evidence regarding the correlation between prostate-specific antigen (PSA) kinetics and clinical outcomes. Therefore, after regulating other covariates, we studied patients with castration-resistant prostate cancer who received
Hong Du   +6 more
doaj   +1 more source

Prognostic Impact of Intraductal Carcinoma in Patients with Metastatic Prostate Cancer Treated with Abiraterone Acetate or Enzalutamide

open access: yesBulletin of Urooncology
Objective: This study aimed to evaluate the prognostic impact of intraductal carcinoma of the prostate (IDC-P) in patients with metastatic prostate cancer treated with enzalutamide or abiraterone acetate.
Hatice Bölek   +3 more
doaj   +1 more source

Comparison of PSA Response to Generic Versus Innovator (Zytiga) Formulations of Abiraterone in Metastatic CRPC: A Retrospective Analysis

open access: yesIndian Journal of Medical and Paediatric Oncology
Introduction Abiraterone acetate has been shown to enhance overall survival and radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC).
Sharath Kumar   +7 more
doaj   +1 more source

Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients

open access: yesPharmacogenomics and Personalized Medicine, 2020
Xiang Wu,1,2 Qing-Jiang Xu,1,2 Ping-Zhou Chen,1,2 Chen-Bo Yu,1,2 Lie-Fu Ye,1,2 Tao Li1,2 1Provincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, People’s Republic of China; 2Department of Urology, Fujian Provincial ...
Wu X, Xu QJ, Chen PZ, Yu CB, Ye LF, Li T
doaj  

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives

open access: yesCancer Management and Research, 2017
Joelle El-Amm,1 Rami Nassabein,1 Jeanny B Aragon-Ching2 1Division of Hematology and Oncology, Department of Internal Medicine, Lebanese American University, Beirut, Lebanon; 2GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA Abstract ...
El-Amm J, Nassabein R, Aragon-Ching JB
doaj  

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer

open access: yesDrug Design, Development and Therapy, 2012
Yasser Rehman1, Jonathan E Rosenberg21Division of Hospital Medicine, UMass Memorial Healthcare, Worcester, MA, USA; 2Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Prostate cancer is
Rosenberg JE, Rehman Y
doaj  

Home - About - Disclaimer - Privacy